The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Depletion of CXCR2 Inhibits Tumor Growth and Angiogenesis in a Murine Model of Lung Cancer
Open accessAbstract
The Glu-Leu-Arg+ (ELR+) CXC chemokines are potent promoters of angiogenesis and have been demonstrated to induce a significant portion of nonsmall cell lung cancer-derived angiogenic activity and support tumorigenesis. ELR+ CXC chemokines share a common chemokine receptor, CXCR2. We hypothesized that CXCR2 mediates the proangiogenic effects of ELR+ CXC chemokines during tumorigenesis. To test this postulate, we used syngeneic murine Lewis lung cancer (LLC; 3LL, H-2b) heterotopic and orthotopic tumor model systems in C57BL/6 mice replete (CXCR2+/+) and deficient in CXCR2 (CXCR2−/−). We first demonstrated a correlation of the expression of endogenous ELR+ CXC chemokines with tumor growth and metastatic potential of LLC tumors. Next, we found that LLC primary tumors were significantly reduced in growth in CXCR2−/− mice. Moreover, we found a marked reduction in the spontaneous metastases of heterotopic tumors to the lungs of CXCR2−/− mice. Morphometric analysis of the primary tumors in CXCR2−/− mice demonstrated increased necrosis and reduced vascular density. These findings were further confirmed in CXCR2+/+ mice using specific neutralizing Abs to CXCR2. The results of these studies support the notion that CXCR2 mediates the angiogenic activity of ELR+ CXC chemokines in a preclinical model of lung cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Li, A., Dubey, S., Varney, M. L., Dave, B. J., & Singh, R. K. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.6.3369 · Cited by 1,332
The Functional Role of the ELR Motif in CXC Chemokine-mediated Angiogenesis
Strieter, R. M., Polverini, P. J., Kunkel, S. L., Arenberg, D. A., Burdick, M. D., Kasper, J., Dzuiba, J., Van Damme, J., Walz, A., Marriott, D., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.45.27348 · Cited by 1,222 · cited 1×
“In contrast, the IFN-inducible ELR CXC chemokines are chemoattractants for mononuclear cells and are potent inhibitors of angiogenesis (37, 38).”
BackgroundSelf-citationFidler, I. J. (1990) · PubMed · Cited by 1,139
Cloning of Complementary DNA Encoding a Functional Human Interleukin-8 Receptor
Murphy, P. M., & Tiffany, H. L. (1991) · Science · doi:10.1126/science.1891716 · Cited by 871
Neutrophil and B Cell Expansion in Mice That Lack the Murine IL-8 Receptor Homolog
Cacalano, G., Lee, J., Kikly, K., Ryan, A. M., Pitts-Meek, S., Hultgren, B., Wood, W. I., & Moore, M. W. (1994) · Science · doi:10.1126/science.8036519 · Cited by 664
Addison, C. L., Daniel, T. O., Burdick, M. D., Liu, H., Ehlert, J. E., Xue, Y. Y., Buechi, L., Walz, A., Richmond, A., & Strieter, R. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.9.5269 · Cited by 575
Self-citationPhillips, R. J., Burdick, M. D., Lutz, M., Belperio, J. A., Keane, M. P., & Strieter, R. M. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200301-071oc · Cited by 455
Self-citationLuster, A. D., Greenberg, S. M., & Leder, P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.1.219 · Cited by 446
Delayed Wound Healing in CXCR2 Knockout Mice
Devalaraja, R. M., Nanney, L. B., Qian, Q., Du, J., Yu, Y., Devalaraja, M. N., & Richmond, A. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00034.x · Cited by 429
Effect of p53 Status on Tumor Response to Antiangiogenic Therapy
Yu, J. L., Rak, J. W., Coomber, B. L., Hicklin, D. J., & Kerbel, R. S. (2002) · Science · doi:10.1126/science.1068327 · Cited by 426
Cited by
Tumor angiogenesis: causes, consequences, challenges and opportunities
Lugano, R., Ramachandran, M., & Dimberg, A. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03351-7 · Cited by 1,986
Neutrophils in cancer: Neutral no more
Coffelt, S. B., Wellenstein, M. D., & de Visser, K. E. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.52 · Cited by 1,830
The role of myeloid cells in the promotion of tumour angiogenesis
Murdoch, C., Muthana, M., Coffelt, S. B., & Lewis, C. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2444 · Cited by 1,642
G-protein-coupled receptors and cancer
Dorsam, R. T., & Gutkind, J. S. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2069 · Cited by 1,388
Bernhagen, J., Krohn, R., Lue, H., Gregory, J. L., Zernecke, A., Koenen, R. R., Dewor, M., Georgiev, I., Schober, A., Leng, L., et al. (2007) · Nature Medicine · doi:10.1038/nm1567 · Cited by 1,269
CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow
Eash, K. J., Greenbaum, A. M., Gopalan, P. K., & Link, D. C. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41649 · Cited by 791
Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases
Ha, H., Debnath, B., & Neamati, N. (2017) · Theranostics · doi:10.7150/thno.15625 · Cited by 789
Tumor-Associated Neutrophils: New Targets for Cancer Therapy
Gregory, A. D., & McGarry Houghton, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2583 · Cited by 707
The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases
Russo, R. C., Garcia, C. C., Teixeira, M. M., & Amaral, F. A. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.894886 · Cited by 647
Role of chemokines in tumor growth
Raman, D., Baugher, P. J., Thu, Y. M., & Richmond, A. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.05.013 · Cited by 578
Miao, Z., Luker, K. E., Summers, B. C., Berahovich, R., Bhojani, M. S., Rehemtulla, A., Kleer, C. G., Essner, J. J., Nasevicius, A., Luker, G. D., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610444104 · Cited by 533
Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice
Shahangian, A., Chow, E. K., Tian, X., Kang, J. R., Ghaffari, A., Liu, S. Y., Belperio, J. A., Cheng, G., & Deng, J. C. (2009) · Journal of Clinical Investigation · doi:10.1172/jci35412 · Cited by 479
Self-citationNeutrophils in Cancer: Two Sides of the Same Coin
Uribe-Querol, E., & Rosales, C. (2015) · Journal of Immunology Research · doi:10.1155/2015/983698 · Cited by 422
Numasaki, M., Watanabe, M., Suzuki, T., Takahashi, H., Nakamura, A., McAllister, F., Hishinuma, T., Goto, J., Lotze, M. T., Kolls, J. K., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.6177 · Cited by 416
CXC chemokines in angiogenesis
Strieter, R. M., Burdick, M. D., Gomperts, B. N., Belperio, J. A., & Keane, M. P. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.04.007 · Cited by 414
Self-citationCancer CXC chemokine networks and tumour angiogenesis
Strieter, R. M., Burdick, M. D., Mestas, J., Gomperts, B., Keane, M. P., & Belperio, J. A. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.006 · Cited by 410
Self-citationKorbecki, J., Simińska, D., Gąssowska-Dobrowolska, M., Listos, J., Gutowska, I., Chlubek, D., & Baranowska-Bosiacka, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910701 · Cited by 380
Interleukin-8 in cancer pathogenesis, treatment and follow-up
Alfaro, C., Sanmamed, M. F., Rodríguez-Ruiz, M. E., Teijeira, Á., Oñate, C., González, Á., Ponz, M., Schalper, K. A., Pérez-Gracia, J. L., & Melero, I. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.004 · Cited by 372
Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases
Cheng, Y., Ma, X.-L., Wei, Y.-Q., & Wei, X.-W. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.01.005 · Cited by 344
Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene
Borrello, M. G., Alberti, L., Fischer, A., Degl'Innocenti, D., Ferrario, C., Gariboldi, M., Marchesi, F., Allavena, P., Greco, A., Collini, P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503039102 · Cited by 331
Critical role of endothelial CXCR2 in LPS-induced neutrophil migration into the lung
Reutershan, J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27009 · Cited by 322
Role of the tumor microenvironment in tumor progression and the clinical applications (Review)
YUAN, Y., JIANG, Y.-C., SUN, C.-K., & CHEN, Q.-M. (2016) · Oncology Reports · doi:10.3892/or.2016.4660 · Cited by 320
Neutrophils: key mediators of tumour angiogenesis
Tazzyman, S., Lewis, C. E., & Murdoch, C. (2009) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2009.00641.x · Cited by 318
Lee, Y. S., Choi, I., Ning, Y., Kim, N. Y., Khatchadourian, V, Yang, D., Chung, H. K., Choi, D., LaBonte, M. J., Ladner, R. D., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.177 · Cited by 292
Nakao, S., Kuwano, T., Tsutsumi-Miyahara, C., Ueda, S.-I., Kimura, Y. N., Hamano, S., Sonoda, K.-H., Saijo, Y., Nukiwa, T., Strieter, R. M., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23298 · Cited by 286
Self-citationNeutrophils in innate and adaptive immunity
Jaillon, S., Galdiero, M. R., Del Prete, D., Cassatella, M. A., Garlanda, C., & Mantovani, A. (2013) · Seminars in Immunopathology · doi:10.1007/s00281-013-0374-8 · Cited by 285
Macrophage Migration Inhibitory Factor in Cardiovascular Disease
Zernecke, A., Bernhagen, J., & Weber, C. (2008) · Circulation · doi:10.1161/circulationaha.107.729125 · Cited by 280
Hepatic platelet and leukocyte adherence during endotoxemia
Croner, R. S., Hoerer, E., Kulu, Y., Hackert, T., Gebhard, M.-M., Herfarth, C., & Klar, E. (2006) · Critical Care · doi:10.1186/cc3968 · Cited by 275
The role of CXC chemokines in pulmonary fibrosis
Strieter, R. M., Gomperts, B. N., & Keane, M. P. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30562 · Cited by 273
Self-citationCancer Inflammation and Cytokines
Galdiero, M. R., Marone, G., & Mantovani, A. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028662 · Cited by 267
CXC Chemokines in Cancer Angiogenesis and Metastases
(2010) · Advances in Cancer Research · doi:10.1016/s0065-230x(10)06003-3 · Cited by 263
Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin
Shi, H., Huang, Y., Zhou, H., Song, X., Yuan, S., Fu, Y., & Luo, Y. (2007) · Blood · doi:10.1182/blood-2007-01-064428 · Cited by 258
The chemokine system – a major regulator of angiogenesis in health and disease
ROSENKILDE, M. M., & SCHWARTZ, T. W. (2004) · APMIS · doi:10.1111/j.1600-0463.2004.apm11207-0808.x · Cited by 255
CXCR2 antagonists for the treatment of pulmonary disease
Chapman, R. W., Phillips, J. E., Hipkin, R. W., Curran, A. K., Lundell, D., & Fine, J. S. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.10.005 · Cited by 214
Chemokines as mediators of neovascularization
Keeley, E. C., Mehrad, B., & Strieter, R. M. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.162925 · Cited by 192
Self-citationTargeting key steps in metastatic tumour progression
Eccles, S. A. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.001 · Cited by 73
Support of Tumor Endothelial Cells by Chemokine Receptors
Salazar, N., & Zabel, B. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00147 · Cited by 72
Maysami, S., Nguyen, D., Zobel, F., Heine, S., Höpfner, M., & Stangel, M. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.05.021 · Cited by 25
Metadata
- Authors
- Keane, M. P., Belperio, J. A., Xue, Y. Y., Burdick, M. D., & Strieter, R. M.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-03-01
- Volume
- 172
- Issue
- 5
- Pages
- 2853-2860
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2134055933
- Cited by
- 305
- References
- 48
- FWCI
- 6.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.